Viatris CCO Corinne Le Goff Sells 7032 Shares for $71,590 on Sept 11
PorAinvest
viernes, 12 de septiembre de 2025, 6:07 pm ET1 min de lectura
TBPH--
Revenues for the second quarter totaled $26.2 million, which was a 83.2% increase year-over-year. This was driven by increased collaboration revenues from partner Viatris and licensing revenues. Specifically, revenues from the Viatris collaboration reached $18.7 million, up 31% year-over-year, and the company received a milestone payment of $7.5 million from Viatris following the approval of Yupelri in China [1].
Research and development expenses (excluding share-based compensation) totaled $9.5 million, an increase of almost 8% from the year-ago quarter. Selling, general, and administrative expenses (excluding share-based compensation) also increased by around 16.4% year-over-year to $12.8 million [1].
As of June 30, 2025, Theravance had $338.8 million in cash, cash equivalents, and marketable securities compared to $130.9 million as of March 31, 2025 [1].
The company reaffirmed its financial guidance for 2025, expecting adjusted R&D expenses to be in the range of $32-$38 million, adjusted SG&A expenses to be between $50 million and $60 million, and share-based compensation expenses to be $18-$20 million. The company expects adjusted losses and cash burn in 2025 to be similar to 2024 levels [1].
Investors have been optimistic about the stock, with estimates trending upward and a VGM Score of A [1]. However, the stock has a Zacks Rank of #3 (Hold), suggesting an in-line return in the next few months [1].
In other news, Viatris Inc. has announced that Chief Commercial Officer Corinne Le Goff sold 7,032 shares at a price of $10.25 per share on September 11, 2025 [2]. This insider trading activity may indicate a shift in the company's outlook or a change in the executive's personal financial strategy.
VTRS--
Viatris Inc. has announced that Chief Commercial Officer Corinne Le Goff has recently sold 7,032 shares at a price of $10.25 per share on September 11, 2025.
Theravance Biopharma (TBPH) has seen a significant increase in its stock price following its most recent earnings report. Shares have added about 9.8% in the past month, outperforming the S&P 500 [1]. The company reported a narrower-than-expected adjusted net loss of 8 cents per share for the second quarter of 2025, compared to the Zacks Consensus Estimate of a 14-cent loss. This was an improvement over the year-ago quarter, where the company incurred an adjusted loss of 13 cents per share [1].Revenues for the second quarter totaled $26.2 million, which was a 83.2% increase year-over-year. This was driven by increased collaboration revenues from partner Viatris and licensing revenues. Specifically, revenues from the Viatris collaboration reached $18.7 million, up 31% year-over-year, and the company received a milestone payment of $7.5 million from Viatris following the approval of Yupelri in China [1].
Research and development expenses (excluding share-based compensation) totaled $9.5 million, an increase of almost 8% from the year-ago quarter. Selling, general, and administrative expenses (excluding share-based compensation) also increased by around 16.4% year-over-year to $12.8 million [1].
As of June 30, 2025, Theravance had $338.8 million in cash, cash equivalents, and marketable securities compared to $130.9 million as of March 31, 2025 [1].
The company reaffirmed its financial guidance for 2025, expecting adjusted R&D expenses to be in the range of $32-$38 million, adjusted SG&A expenses to be between $50 million and $60 million, and share-based compensation expenses to be $18-$20 million. The company expects adjusted losses and cash burn in 2025 to be similar to 2024 levels [1].
Investors have been optimistic about the stock, with estimates trending upward and a VGM Score of A [1]. However, the stock has a Zacks Rank of #3 (Hold), suggesting an in-line return in the next few months [1].
In other news, Viatris Inc. has announced that Chief Commercial Officer Corinne Le Goff sold 7,032 shares at a price of $10.25 per share on September 11, 2025 [2]. This insider trading activity may indicate a shift in the company's outlook or a change in the executive's personal financial strategy.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
SOBRE NOSOTROS
Nuestra historiaAutores de noticiasBase de conocimientosPolítica de privacidadTérmino de usoDescargo de responsabilidad de corretaje de tercerosTérminos de uso de AIMEDivulgaciones de riesgos de AInvest AICarrerasCONTÁCTENOS
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comentarios
Aún no hay comentarios